• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

如何识别发生鼻型、结外自然杀伤/T细胞淋巴瘤相关噬血细胞综合征高危患者。

How to Identify Patients at High Risk of Developing Nasal-Type, Extranodal Nature Killer/T-Cell Lymphoma-Associated Hemophagocytic Syndrome.

作者信息

Li Na, Jiang Ming, Wu Wan-Chun, Wei Wen-Wen, Zou Li-Qun

机构信息

Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

Department of Oncology, West China Fourth Hospital, Sichuan University, Chengdu, China.

出版信息

Front Oncol. 2021 Aug 18;11:704962. doi: 10.3389/fonc.2021.704962. eCollection 2021.

DOI:10.3389/fonc.2021.704962
PMID:34490105
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8416502/
Abstract

Nasal-type, extranodal nature killer (NK)/T-cell lymphoma-associated hemophagocytic syndrome (NK/T-LAHS) is a rare and life-threatening disease, requiring investigation of risk stratification. We conducted a retrospective study and proposed nomograms to predict NK/T-LAHS. The discriminative ability and calibration of the nomograms for prediction were tested using C statistics and calibration plots. We analyzed 533 patients with extranodal NK/T-cell lymphoma (ENKTL), out of which 71 were diagnosed with hemophagocytic syndrome (HPS), with a cumulative incidence of 13.3%. Significant difference for 2-year survival was found between patients with and without HPS (14.7% 77.5%). Analyses showed that Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥2, B symptoms, and bone marrow (BM) invasion were significantly associated with NK/T-LAHS. We used these data as the basis to establish a nomogram of risk index for ENKTL (RINK). In 335 patients with available data for Epstein-Barr virus DNA (EBV-DNA), we found high viral copies (≥4,450 copies/ml) were correlated with NK/T-LAHS. When these data were added to RINK, we developed another nomogram that included EBV-DNA data (RINK-E). The nomograms displayed good accuracy in predicting NK/T-LAHS with a C-statistics of 0.919 for RINK and a C-statistics of 0.946 for RINK-E, respectively. The calibration chart also showed an excellent consistency between the predicted and observed probabilities. The proposed nomograms provided individualized risk estimate of HPS in patients with ENKTL.

摘要

鼻型、结外自然杀伤(NK)/T细胞淋巴瘤相关噬血细胞综合征(NK/T-LAHS)是一种罕见且危及生命的疾病,需要对风险分层进行研究。我们进行了一项回顾性研究并提出列线图以预测NK/T-LAHS。使用C统计量和校准图对预测列线图的判别能力和校准进行了测试。我们分析了533例结外NK/T细胞淋巴瘤(ENKTL)患者,其中71例被诊断为噬血细胞综合征(HPS),累积发病率为13.3%。有HPS和无HPS的患者之间2年生存率存在显著差异(14.7%对77.5%)。分析表明,东部肿瘤协作组(ECOG)体能状态(PS)≥2、B症状和骨髓(BM)侵犯与NK/T-LAHS显著相关。我们以这些数据为基础建立了ENKTL风险指数列线图(RINK)。在335例有可用爱泼斯坦-巴尔病毒DNA(EBV-DNA)数据的患者中,我们发现高病毒拷贝数(≥4450拷贝/ml)与NK/T-LAHS相关。当将这些数据添加到RINK中时,我们开发了另一个包含EBV-DNA数据的列线图(RINK-E)。RINK和RINK-E列线图在预测NK/T-LAHS方面显示出良好的准确性,C统计量分别为0.919和0.946。校准图也显示预测概率和观察概率之间具有良好的一致性。所提出的列线图为ENKTL患者的HPS提供了个体化风险估计。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1d/8416502/4cbc489f64ab/fonc-11-704962-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1d/8416502/8787db390916/fonc-11-704962-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1d/8416502/8f36359d5119/fonc-11-704962-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1d/8416502/d10fb8cecf00/fonc-11-704962-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1d/8416502/80f1b3201850/fonc-11-704962-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1d/8416502/4cbc489f64ab/fonc-11-704962-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1d/8416502/8787db390916/fonc-11-704962-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1d/8416502/8f36359d5119/fonc-11-704962-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1d/8416502/d10fb8cecf00/fonc-11-704962-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1d/8416502/80f1b3201850/fonc-11-704962-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a1d/8416502/4cbc489f64ab/fonc-11-704962-g005.jpg

相似文献

1
How to Identify Patients at High Risk of Developing Nasal-Type, Extranodal Nature Killer/T-Cell Lymphoma-Associated Hemophagocytic Syndrome.如何识别发生鼻型、结外自然杀伤/T细胞淋巴瘤相关噬血细胞综合征高危患者。
Front Oncol. 2021 Aug 18;11:704962. doi: 10.3389/fonc.2021.704962. eCollection 2021.
2
A clinical study of 21 patients with hemophagocytic syndrome in 295 cases diagnosed with nasal type, extranodal nature killer/T cell lymphoma.对295例诊断为鼻型、结外自然杀伤/ T细胞淋巴瘤患者中的21例噬血细胞综合征患者进行的临床研究。
Cancer Biol Ther. 2017 Apr 3;18(4):252-256. doi: 10.1080/15384047.2017.1295176. Epub 2017 Feb 25.
3
Clinical features and treatment of natural killer/T cell lymphoma associated with hemophagocytic syndrome: comparison with other T cell lymphoma associated with hemophagocytic syndrome.自然杀伤/T细胞淋巴瘤合并噬血细胞综合征的临床特征与治疗:与其他合并噬血细胞综合征的T细胞淋巴瘤的比较
Leuk Lymphoma. 2014 Sep;55(9):2048-55. doi: 10.3109/10428194.2013.876629. Epub 2014 Feb 24.
4
Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome.伴有和不伴有噬血细胞综合征的结外自然杀伤/T细胞淋巴瘤的临床特征与生存情况
Ann Hematol. 2016 Dec;95(12):2023-2031. doi: 10.1007/s00277-016-2805-9. Epub 2016 Sep 6.
5
Lymphoma-associated hemophagocytic syndrome: a retrospective study from a single center.淋巴瘤相关噬血细胞综合征:来自单个中心的回顾性研究。
Hematology. 2022 Dec;27(1):909-916. doi: 10.1080/16078454.2022.2113600.
6
The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.基于抗PD-1抗体的治疗方案在结外NK/T细胞淋巴瘤相关噬血细胞性淋巴组织细胞增生症治疗中的新兴作用。
J Cancer Res Clin Oncol. 2023 May;149(5):2017-2027. doi: 10.1007/s00432-022-04147-2. Epub 2022 Jul 9.
7
A clinicopathological study of 20 patients with T/natural killer (NK)-cell lymphoma-associated hemophagocytic syndrome with special reference to nasal and nasal-type NK/T-cell lymphoma.20例T/自然杀伤(NK)细胞淋巴瘤相关噬血细胞综合征患者的临床病理研究,特别提及鼻型和鼻型NK/T细胞淋巴瘤
Int J Hematol. 2001 Oct;74(3):303-8. doi: 10.1007/BF02982065.
8
Lymphoma-associated hemophagocytic syndrome: a retrospective, single-center study of 86 patients.淋巴瘤相关噬血细胞综合征:86 例回顾性单中心研究。
Ann Hematol. 2024 Sep;103(9):3649-3656. doi: 10.1007/s00277-024-05900-y. Epub 2024 Jul 30.
9
Lymphoma associated hemophagocytic syndrome: A single-center retrospective study.淋巴瘤相关噬血细胞综合征:一项单中心回顾性研究。
Oncol Lett. 2018 Jul;16(1):1275-1284. doi: 10.3892/ol.2018.8783. Epub 2018 May 22.
10
[Clinical characteristics and prognosis of lymphoma-associated hemophagocytic syndrome].[淋巴瘤相关噬血细胞综合征的临床特征与预后]
Zhonghua Yi Xue Za Zhi. 2022 Jul 26;102(28):2173-2180. doi: 10.3760/cma.j.cn112137-20220221-00349.

引用本文的文献

1
Prognostic role of prognostic nutritional index in patients with lymphoma-associated hemophagocytic lymphohistiocytosis.预后营养指数在淋巴瘤相关噬血细胞性淋巴组织细胞增生症患者中的预后作用
Future Oncol. 2025 Jun;21(15):1879-1886. doi: 10.1080/14796694.2025.2507565. Epub 2025 May 22.
2
Clinical Efficacy of Programmed Cell Death Ligand 1 Antibody in Treatment of Extranodal Natural Killer/T-Cell Lymphoma With Hemophagocytic Lymphohistiocytosis.程序性细胞死亡配体1抗体治疗伴噬血细胞性淋巴组织细胞增生症的结外自然杀伤/T细胞淋巴瘤的临床疗效
J Hematol. 2024 Apr;13(1-2):46-51. doi: 10.14740/jh1242. Epub 2024 Apr 9.
3
The clinical significance and prognostic value of serum beta-2 microglobulin in adult lymphoma-associated hemophagocytic lymphohistiocytosis: a multicenter analysis of 326 patients.

本文引用的文献

1
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.阿维鲁单抗治疗复发或难治性结外 NK/T 细胞淋巴瘤:一项开放标签的 2 期研究。
Blood. 2020 Dec 10;136(24):2754-2763. doi: 10.1182/blood.2020007247.
2
Pediatric hemophagocytic lymphohistiocytosis.儿童噬血细胞性淋巴组织细胞增生症。
Blood. 2020 Apr 16;135(16):1332-1343. doi: 10.1182/blood.2019000936.
3
Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults.纳武利尤单抗治疗成人复发性/难治性 EBV 相关噬血细胞性淋巴组织细胞增生症。
血清β2-微球蛋白在成人淋巴瘤相关噬血细胞性淋巴组织细胞增生症中的临床意义和预后价值:326 例多中心分析。
Ann Hematol. 2024 Jul;103(7):2257-2266. doi: 10.1007/s00277-024-05631-0. Epub 2024 Jan 25.
4
Intravascular NK/T-Cell Lymphoma: What We Know about This Diagnostically Challenging, Aggressive Disease.血管内NK/T细胞淋巴瘤:关于这种诊断具有挑战性的侵袭性疾病我们所了解的情况。
Cancers (Basel). 2022 Nov 6;14(21):5458. doi: 10.3390/cancers14215458.
5
Spectrum and trigger identification of hemophagocytic lymphohistiocytosis in adults: A single-center analysis of 555 cases.成人噬血细胞性淋巴组织细胞增生症的谱和触发因素分析:单中心 555 例分析。
Front Immunol. 2022 Aug 12;13:970183. doi: 10.3389/fimmu.2022.970183. eCollection 2022.
6
F-FDG PET/CT Plays a Limited Role in Replacing Bone Marrow Biopsy for Newly Diagnosed Advanced-Stage Patients With Extranodal Natural Killer/T-Cell Lymphoma.对于初诊的晚期结外自然杀伤/T细胞淋巴瘤患者,F-FDG PET/CT在替代骨髓活检方面作用有限。
Front Oncol. 2022 Jul 26;12:894804. doi: 10.3389/fonc.2022.894804. eCollection 2022.
7
The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.基于抗PD-1抗体的治疗方案在结外NK/T细胞淋巴瘤相关噬血细胞性淋巴组织细胞增生症治疗中的新兴作用。
J Cancer Res Clin Oncol. 2023 May;149(5):2017-2027. doi: 10.1007/s00432-022-04147-2. Epub 2022 Jul 9.
8
Clinical Features and Prognostic Risk Prediction of Non-Hodgkin Lymphoma-Associated Hemophagocytic Syndrome.非霍奇金淋巴瘤相关噬血细胞综合征的临床特征及预后风险预测
Front Oncol. 2021 Dec 6;11:788056. doi: 10.3389/fonc.2021.788056. eCollection 2021.
Blood. 2020 Mar 12;135(11):826-833. doi: 10.1182/blood.2019003886.
4
A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study.鼻腔型自然杀伤/T 细胞淋巴瘤的临床血液学预后模型:一项多中心研究。
Sci Rep. 2019 Oct 18;9(1):14961. doi: 10.1038/s41598-019-51522-0.
5
Prognostic significance of Epstein-Barr virus DNA in NK/T-cell lymphoma: a meta-analysis.爱泼斯坦-巴尔病毒DNA在NK/T细胞淋巴瘤中的预后意义:一项荟萃分析
Onco Targets Ther. 2018 Feb 26;11:997-1004. doi: 10.2147/OTT.S153942. eCollection 2018.
6
PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety.低剂量纳武单抗阻断程序性死亡蛋白1用于对左旋门冬酰胺酶治疗失败的NK/T细胞淋巴瘤:疗效与安全性
Ann Hematol. 2018 Jan;97(1):193-196. doi: 10.1007/s00277-017-3127-2. Epub 2017 Sep 6.
7
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.西达本胺治疗复发或难治性外周T细胞淋巴瘤:一项中国多中心真实世界研究
J Hematol Oncol. 2017 Mar 15;10(1):69. doi: 10.1186/s13045-017-0439-6.
8
A clinical study of 21 patients with hemophagocytic syndrome in 295 cases diagnosed with nasal type, extranodal nature killer/T cell lymphoma.对295例诊断为鼻型、结外自然杀伤/ T细胞淋巴瘤患者中的21例噬血细胞综合征患者进行的临床研究。
Cancer Biol Ther. 2017 Apr 3;18(4):252-256. doi: 10.1080/15384047.2017.1295176. Epub 2017 Feb 25.
9
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.帕博利珠单抗的 PD1 阻断在 l-天冬酰胺酶治疗失败的复发或难治性 NK/T 细胞淋巴瘤中具有高度疗效。
Blood. 2017 Apr 27;129(17):2437-2442. doi: 10.1182/blood-2016-12-756841. Epub 2017 Feb 10.
10
Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome.伴有和不伴有噬血细胞综合征的结外自然杀伤/T细胞淋巴瘤的临床特征与生存情况
Ann Hematol. 2016 Dec;95(12):2023-2031. doi: 10.1007/s00277-016-2805-9. Epub 2016 Sep 6.